Our group has worked for a long time in the molecular and functional characterization of diverse family of immune receptors including CD150, CD300, Siglecs and LILR. At the present moment, we are focusing our efforts in evaluate the possible role of some of those receptors both as a diagnostic markers and targets for diverse pathologies, including cancer, acute nervous system damage and diabetes. Moreover, we are trying to modulate the function of some of those receptors to increase the circulation time of specific nanoparticles and vesicles used as therapeutic and/or diagnostic tools.
Started 5 September, 2016
5600
